Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1996 Nov;70(11):8247–8251. doi: 10.1128/jvi.70.11.8247-8251.1996

Possible role of the V3 domain of gp120 in resistance to an amphotericin B derivative (MS8209) blocking human immunodeficiency virus entry.

O Pleskoff 1, N Sol 1, H Marrakchi 1, M Serlin 1, M Seman 1, M Alizon 1
PMCID: PMC190911  PMID: 8892962

Abstract

MS8209, an amphotericin B derivative blocking human immunodeficiency virus type 1 (HIV-1) entry after CD4 binding, neutralized the HIV-2 strains EHO and ROD10 but not ROD(CEM). In the V3 domain of gp120, ROD(CEM) differed from ROD10 at two positions (a threonine instead of an isoleucine at position 312 and an arginine instead of a glutamine at position 329), and drug resistance was conferred to HIV-1 by substitution of the ROD(CEM) V3 but not the ROD10 V3. V3 mutations may prevent the interaction of gp120 with MS8209 or modify the mechanism of virus entry, rendering it less accessible to neutralization.

Full Text

The Full Text of this article is available as a PDF (174.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alkhatib G., Combadiere C., Broder C. C., Feng Y., Kennedy P. E., Murphy P. M., Berger E. A. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 1996 Jun 28;272(5270):1955–1958. doi: 10.1126/science.272.5270.1955. [DOI] [PubMed] [Google Scholar]
  2. Aloia R. C., Tian H., Jensen F. C. Lipid composition and fluidity of the human immunodeficiency virus envelope and host cell plasma membranes. Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5181–5185. doi: 10.1073/pnas.90.11.5181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Batinić D., Robey F. A. The V3 region of the envelope glycoprotein of human immunodeficiency virus type 1 binds sulfated polysaccharides and CD4-derived synthetic peptides. J Biol Chem. 1992 Apr 5;267(10):6664–6671. [PubMed] [Google Scholar]
  4. Bolard J. How do the polyene macrolide antibiotics affect the cellular membrane properties? Biochim Biophys Acta. 1986 Dec 22;864(3-4):257–304. doi: 10.1016/0304-4157(86)90002-x. [DOI] [PubMed] [Google Scholar]
  5. Brun-Vezinet F., Rey M. A., Katlama C., Girard P. M., Roulot D., Yeni P., Lenoble L., Clavel F., Alizon M., Gadelle S. Lymphadenopathy-associated virus type 2 in AIDS and AIDS-related complex. Clinical and virological features in four patients. Lancet. 1987 Jan 17;1(8525):128–132. doi: 10.1016/s0140-6736(87)91967-2. [DOI] [PubMed] [Google Scholar]
  6. Callahan L. N., Phelan M., Mallinson M., Norcross M. A. Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions. J Virol. 1991 Mar;65(3):1543–1550. doi: 10.1128/jvi.65.3.1543-1550.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chesebro B., Nishio J., Perryman S., Cann A., O'Brien W., Chen I. S., Wehrly K. Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages. J Virol. 1991 Nov;65(11):5782–5789. doi: 10.1128/jvi.65.11.5782-5789.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Choe H., Farzan M., Sun Y., Sullivan N., Rollins B., Ponath P. D., Wu L., Mackay C. R., LaRosa G., Newman W. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 1996 Jun 28;85(7):1135–1148. doi: 10.1016/s0092-8674(00)81313-6. [DOI] [PubMed] [Google Scholar]
  9. Clapham P. R., Blanc D., Weiss R. A. Specific cell surface requirements for the infection of CD4-positive cells by human immunodeficiency virus types 1 and 2 and by Simian immunodeficiency virus. Virology. 1991 Apr;181(2):703–715. doi: 10.1016/0042-6822(91)90904-P. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Clavel F., Charneau P. Fusion from without directed by human immunodeficiency virus particles. J Virol. 1994 Feb;68(2):1179–1185. doi: 10.1128/jvi.68.2.1179-1185.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Céfai D., Hadida F., Jung M., Debre P., Vernin J. G., Seman M. MS-8209, a new Amphotericin B derivative that inhibits HIV-1 replication in vitro and restores T-cell activation via the CD3/TcR in HIV-infected CD4+ cells. AIDS. 1991 Dec;5(12):1453–1461. doi: 10.1097/00002030-199112000-00007. [DOI] [PubMed] [Google Scholar]
  12. Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., Di Marzio P., Marmon S., Sutton R. E., Hill C. M. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996 Jun 20;381(6584):661–666. doi: 10.1038/381661a0. [DOI] [PubMed] [Google Scholar]
  13. Doranz B. J., Rucker J., Yi Y., Smyth R. J., Samson M., Peiper S. C., Parmentier M., Collman R. G., Doms R. W. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell. 1996 Jun 28;85(7):1149–1158. doi: 10.1016/s0092-8674(00)81314-8. [DOI] [PubMed] [Google Scholar]
  14. Dragic T., Litwin V., Allaway G. P., Martin S. R., Huang Y., Nagashima K. A., Cayanan C., Maddon P. J., Koup R. A., Moore J. P. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996 Jun 20;381(6584):667–673. doi: 10.1038/381667a0. [DOI] [PubMed] [Google Scholar]
  15. Feng Y., Broder C. C., Kennedy P. E., Berger E. A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 1996 May 10;272(5263):872–877. doi: 10.1126/science.272.5263.872. [DOI] [PubMed] [Google Scholar]
  16. Freed E. O., Martin M. A. The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. J Biol Chem. 1995 Oct 13;270(41):23883–23886. doi: 10.1074/jbc.270.41.23883. [DOI] [PubMed] [Google Scholar]
  17. Guyader M., Emerman M., Sonigo P., Clavel F., Montagnier L., Alizon M. Genome organization and transactivation of the human immunodeficiency virus type 2. Nature. 1987 Apr 16;326(6114):662–669. doi: 10.1038/326662a0. [DOI] [PubMed] [Google Scholar]
  18. Hansen J. E., Witzke N. M., Nielsen C., Mathiesen L. R., Teglbjaerg L. S., Nielsen C. M., Nielsen J. O. Derivatives of amphotericin inhibit infection with human immunodeficiency virus in vitro by different modes of action. Antiviral Res. 1990 Sep;14(3):149–159. doi: 10.1016/0166-3542(90)90031-2. [DOI] [PubMed] [Google Scholar]
  19. Harada S., Koyanagi Y., Yamamoto N. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science. 1985 Aug 9;229(4713):563–566. doi: 10.1126/science.2992081. [DOI] [PubMed] [Google Scholar]
  20. Harrop H. A., Coombe D. R., Rider C. C. Heparin specifically inhibits binding of V3 loop antibodies to HIV-1 gp120, an effect potentiated by CD4 binding. AIDS. 1994 Feb;8(2):183–192. doi: 10.1097/00002030-199402000-00005. [DOI] [PubMed] [Google Scholar]
  21. Hwang S. S., Boyle T. J., Lyerly H. K., Cullen B. R. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science. 1991 Jul 5;253(5015):71–74. doi: 10.1126/science.1905842. [DOI] [PubMed] [Google Scholar]
  22. Linsley P. S., Ledbetter J. A., Kinney-Thomas E., Hu S. L. Effects of anti-gp120 monoclonal antibodies on CD4 receptor binding by the env protein of human immunodeficiency virus type 1. J Virol. 1988 Oct;62(10):3695–3702. doi: 10.1128/jvi.62.10.3695-3702.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Matsushita S., Matsumi S., Yoshimura K., Morikita T., Murakami T., Takatsuki K. Neutralizing monoclonal antibodies against human immunodeficiency virus type 2 gp120. J Virol. 1995 Jun;69(6):3333–3340. doi: 10.1128/jvi.69.6.3333-3340.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. McKnight A., Clapham P. R., Weiss R. A. HIV-2 and SIV infection of nonprimate cell lines expressing human CD4: restrictions to replication at distinct stages. Virology. 1994 May 15;201(1):8–18. doi: 10.1006/viro.1994.1260. [DOI] [PubMed] [Google Scholar]
  25. Peden K., Emerman M., Montagnier L. Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI. Virology. 1991 Dec;185(2):661–672. doi: 10.1016/0042-6822(91)90537-l. [DOI] [PubMed] [Google Scholar]
  26. Pleskoff O., Seman M., Alizon M. Amphotericin B derivative blocks human immunodeficiency virus type 1 entry after CD4 binding: effect on virus-cell fusion but not on cell-cell fusion. J Virol. 1995 Jan;69(1):570–574. doi: 10.1128/jvi.69.1.570-574.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Rey-Cuille M. A., Galabru J., Laurent-Crawford A., Krust B., Montagnier L., Hovanessian A. G. HIV-2 EHO isolate has a divergent envelope gene and induces single cell killing by apoptosis. Virology. 1994 Jul;202(1):471–476. doi: 10.1006/viro.1994.1364. [DOI] [PubMed] [Google Scholar]
  28. Rimland J., Xin W., Sweetnam P., Saijoh K., Nestler E. J., Duman R. S. Sequence and expression of a neuropeptide Y receptor cDNA. Mol Pharmacol. 1991 Dec;40(6):869–875. [PubMed] [Google Scholar]
  29. Ryan-Graham M. A., Peden K. W. Both virus and host components are important for the manifestation of a Nef- phenotype in HIV-1 and HIV-2. Virology. 1995 Oct 20;213(1):158–168. doi: 10.1006/viro.1995.1556. [DOI] [PubMed] [Google Scholar]
  30. Sattentau Q. J., Moore J. P. Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med. 1991 Aug 1;174(2):407–415. doi: 10.1084/jem.174.2.407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Schaffner C. P., Plescia O. J., Pontani D., Sun D., Thornton A., Pandey R. C., Sarin P. S. Anti-viral activity of amphotericin B methyl ester: inhibition of HTLV-III replication in cell culture. Biochem Pharmacol. 1986 Nov 15;35(22):4110–4113. doi: 10.1016/0006-2952(86)90037-7. [DOI] [PubMed] [Google Scholar]
  32. Selvam M. P., Blay R. A., Geyer S., Buck S. M., Pollock L., Mayner R. E., Epstein J. S. Inhibition of HIV-1 replication in H9 cells by nystatin-A compared with other antiviral agents. AIDS Res Hum Retroviruses. 1993 May;9(5):475–481. doi: 10.1089/aid.1993.9.475. [DOI] [PubMed] [Google Scholar]
  33. Shioda T., Levy J. A., Cheng-Mayer C. Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature. 1991 Jan 10;349(6305):167–169. doi: 10.1038/349167a0. [DOI] [PubMed] [Google Scholar]
  34. Skinner M. A., Langlois A. J., McDanal C. B., McDougal J. S., Bolognesi D. P., Matthews T. J. Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. J Virol. 1988 Nov;62(11):4195–4200. doi: 10.1128/jvi.62.11.4195-4200.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Wyatt J. R., Vickers T. A., Roberson J. L., Buckheit R. W., Jr, Klimkait T., DeBaets E., Davis P. W., Rayner B., Imbach J. L., Ecker D. J. Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1356–1360. doi: 10.1073/pnas.91.4.1356. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES